Have the National Institute for Biomedical Research and Development carry out full-cycle development of drugs, devices, and biological products to lower drug prices and improve access to medicines.

Rashida Tlaib · Michigan · Democratic

policy impact 4.00 specificity 1.00 extraction confidence 95%

Contest this claim

Occurrences

The National Institute for Biomedical Research and Development, as part of the National Institutes of Health, will engage in the full-cycle development of drugs, devices, and biological products to reduce drug prices, promote access to medicines, foster scientific innovation, and address public health priorities.

The proposed institute would develop medical products end-to-end with the goal of reducing prices and improving access.

Tlaib Introduces the Medicines for the People Act
primary · press_release · model gpt-5.4-mini

Evidence

The official House homepage shows Tlaib's most recent posted action on June 18, 2026: the Find Our Families Act on ICE/CBP detainee locator systems. The other visible recent posts in May focus on child poverty, the Nakba, and utility penalties, not drug pricing or biomedical-development policy.

Recent official activity is on immigration and other priorities, with no visible sign of the promised medicines-development effort.

unresolved unknown

Home
secondary · model gpt-5.4-mini · confidence 46%

Contest this evidence item

A search within the current official homepage content found no matches for 'drug' or 'medicine', and the visible issue sections are Justice for All, Ending Poverty, and Environmental Justice. That leaves no current House-page sign that the specific biomedical research and drug-development promise has been implemented.

The current official House page does not show the promised drug-development program or related language.

unresolved unknown

Home
secondary · model gpt-5.4-mini · confidence 39%

Contest this evidence item

Assessments

unresolved unknown

The available evidence does not show Rashida Tlaib advancing, sponsoring, or achieving the specific biomedical-development program. Her recent official activity is on unrelated issues, and the current House site shows no sign of the promised drug-development initiative, so the claim cannot be credited as delivered.

provider codex_cli · model gpt-5.4-mini · confidence 81%